Ironwood Pharmaceuticals
IRWD
212 hedge funds and large institutions have $2B invested in Ironwood Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 70 increasing their positions, 78 reducing their positions, and 43 closing their positions.
524% more call options, than puts
Call options by funds: $8.35M | Put options by funds: $1.34M
3.89% less ownership
Funds ownership: 108.92% → 105.03% (-3.9%)
7% less funds holding
Funds holding: 227 → 212 (-15)
10% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 78
14% less capital invested
Capital invested by funds: $2.31B → $2B (-$314M)
30% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 43
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$23.3M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$15.2M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$6.99M |
| 4 |
RA
Royce & Associates
New York
|
+$5.9M |
| 5 |
Renaissance Technologies
New York
|
+$5.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$30.7M |
| 2 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$22.2M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$17.3M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$12.1M |
| 5 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
-$9.16M |
IRWD Hedge Fund Activity: Q4 2021 in Review
212 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q4 2021, worth a combined $2B — down 14% from $2.31B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of IRWD and 30 opened new positions — a net loss of 13 holders — while 78 trimmed existing stakes and 70 added.
The largest buyer was BlackRock, adding an estimated $23.3M. The largest seller was Camber Capital Management, cutting an estimated $30.7M.
- 212 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q4 2021, down from 227 in Q3 2021.
- Funds reported $2B of Ironwood Pharmaceuticals stock for Q4 2021, down 14% quarter-over-quarter.
- 30 funds opened new Ironwood Pharmaceuticals positions in Q4 2021 and 43 closed out, a net change of -13 holders.
- The largest Ironwood Pharmaceuticals buyer in Q4 2021 was BlackRock, an estimated $23.3M added.
- The largest Ironwood Pharmaceuticals seller in Q4 2021 was Camber Capital Management, an estimated $30.7M sold.
Based on aggregated 13F filings for Q4 2021.